Avanir Pharmaceuticals (AVNR) Reports In-Line Q4 Loss of 9c/Share

December 12, 2012 4:02 PM EST
Get Alerts AVNR Hot Sheet
Trade AVNR Now!
Join SI Premium – FREE
Avanir Pharmaceuticals (NASDAQ: AVNR) reported Q4 EPS of ($0.09), in-line with the analyst estimate of ($0.09). Revenue for the quarter came in at $13.5 million versus the consensus estimate of $12.9 million.

For earnings history and earnings-related data on Avanir Pharmaceuticals (AVNR) click here.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories


Related Entities


Add Your Comment